Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 9, 2011 - Issue 7
Submit an article Journal homepage
2,330
Views
93
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-Extension study)

Erica Romualdi Research Centre on Thromboembolic Disorders and on Antithrombotic Therapies, Department of Clinical Medicine, University of Insubria, Varese, Italy;[email protected]
,
Marco P Donadini Research Centre on Thromboembolic Disorders and on Antithrombotic Therapies, Department of Clinical Medicine, University of Insubria, Varese, Italy; Research Centre on Thromboembolic Disorders and on Antithrombotic Therapies, Department of Clinical Medicine, University of Insubria, Varese, Italy
&
Walter Ageno Research Centre on Thromboembolic Disorders and on Antithrombotic Therapies, Department of Clinical Medicine, University of Insubria, Varese, Italy; UO Medicina I, Ospedale di Circolo, Viale Borri 57, 21100 Varese, Italy; Research Centre on Thromboembolic Disorders and on Antithrombotic Therapies, Department of Clinical Medicine, University of Insubria, Varese, Italy; UO Medicina I, Ospedale di Circolo, Viale Borri 57, 21100 Varese, Italy
Pages 841-844 | Published online: 10 Jan 2014

References

  • Witt DM, Delate T, Clarck NP et al. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood114, 952–956 (2009).
  • Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorragic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical practice guidelines (8th Edition). Chest33, 257–298 (2008).
  • Prandoni P, Noventa F, Ghirarduzzi A et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica92, 199–205 (2007).
  • Iorio A, Kearon C, Filippucci E et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch. Intern. Med.170, 1710–1716 (2010).
  • Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J. Clin. Oncol.18, 3078–3083 (2003).
  • Kearon C, Kahn SR, Agnelli G et al. Antithrombotic therapy for venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines. Chest133, 454–545 (2008).
  • Lee AY, Levien MN. Venous thromboembolism and cancer: risks and outcomes. Circulation107, I17–I21 (2003).
  • Turpie AG. Oral Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscl. Thromb. Vasc. Biol.27, 1238–1247 (2007).
  • Perzborn E, Strassburger J, Wilmen A et al. In vitro and in vivo studies of the novel antithrombotic agent BAY59–7939 an oral direct Factor Xa inhibitor. J. Thromb. Haemost.3, 514–521 (2005).
  • Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of Factor Xa in determining the procoagulant activity of whole-blood clots. J. Clin. Invest.91, 1877–1883 (1993).
  • Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of Factor Xa in determining the procoagulant activity of whole-blood clots. J. Clin. Invest.91, 1877–1883 (1993).
  • Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety pharmacodynamics and pharmacokinetics of BAY39–7959, an oral direct Factor Xa inhibitor. Clin. Pharmacol. Ther.78, 412–421 (2005).
  • Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety pharmacodynamics and pharmacokinetics of BAY39–7959, an oral direct Factor Xa inhibitor after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol.61, 873–880 (2005).
  • Kubitza D, Haas S. Novel Factor Xa inhibitors for the prevention and treatment of thromboembolic diseases. Expert Opin. Investig. Drugs15, 843–855 (2006).
  • Kubitza D, Becka M, Mueck W et al. The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban – an oral direct Factor Xa inhibitor. Blood108 (2006) (Abstract 905).
  • Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics of rivaroxaban (BAY 59-7939) in healthy subjects. Int. J. Clin. Pharmacol. Ther.45, 335–344 (2007).
  • Agnelli G, Gallus A, Goldhaber S et al. Treatment of proximal deep venous thrombosis with the oral, direct Factor Xa inhibitor rivaroxaban (BAY59–7939) – the ODIXa DVT (oral direct Factor Xa inhibitor BAY59–7939 in patients with acute symptomatic deep vein thrombosis) study. Circulation116, 180–187 (2007).
  • Buller HR, Lensing AW, Prins MH et al. A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the EINSTEIN-DVT Dose-Ranging Study. Blood112, 2242–2272 (2008).
  • EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med.363, 2499–2510 (2010).
  • Agnelli G, Prandoni P, Santamaria MG et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N. Engl. J. Med.345, 165–169 (2001).
  • Agnelli G, Prandoni P, Becattini C et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann. Inter. Med.139, 19–25 (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.